S&P 500   3,624.92 (+1.10%)
DOW   29,078.49 (+1.23%)
QQQ   269.11 (+0.69%)
AAPL   138.12 (-0.06%)
MSFT   235.25 (+1.01%)
META   136.82 (+0.84%)
GOOGL   96.71 (+1.11%)
AMZN   113.66 (+0.58%)
TSLA   247.40 (-6.73%)
NVDA   122.36 (+0.80%)
NIO   15.48 (-1.84%)
BABA   79.04 (-1.19%)
AMD   64.36 (+1.58%)
T   15.84 (+3.26%)
MU   51.05 (+1.90%)
CGC   2.73 (+0.00%)
F   11.20 (+0.00%)
GE   62.42 (+0.82%)
DIS   95.08 (+0.80%)
AMC   6.77 (-2.87%)
PYPL   86.16 (+0.10%)
PFE   44.07 (+0.71%)
NFLX   236.51 (+0.45%)
S&P 500   3,624.92 (+1.10%)
DOW   29,078.49 (+1.23%)
QQQ   269.11 (+0.69%)
AAPL   138.12 (-0.06%)
MSFT   235.25 (+1.01%)
META   136.82 (+0.84%)
GOOGL   96.71 (+1.11%)
AMZN   113.66 (+0.58%)
TSLA   247.40 (-6.73%)
NVDA   122.36 (+0.80%)
NIO   15.48 (-1.84%)
BABA   79.04 (-1.19%)
AMD   64.36 (+1.58%)
T   15.84 (+3.26%)
MU   51.05 (+1.90%)
CGC   2.73 (+0.00%)
F   11.20 (+0.00%)
GE   62.42 (+0.82%)
DIS   95.08 (+0.80%)
AMC   6.77 (-2.87%)
PYPL   86.16 (+0.10%)
PFE   44.07 (+0.71%)
NFLX   236.51 (+0.45%)
S&P 500   3,624.92 (+1.10%)
DOW   29,078.49 (+1.23%)
QQQ   269.11 (+0.69%)
AAPL   138.12 (-0.06%)
MSFT   235.25 (+1.01%)
META   136.82 (+0.84%)
GOOGL   96.71 (+1.11%)
AMZN   113.66 (+0.58%)
TSLA   247.40 (-6.73%)
NVDA   122.36 (+0.80%)
NIO   15.48 (-1.84%)
BABA   79.04 (-1.19%)
AMD   64.36 (+1.58%)
T   15.84 (+3.26%)
MU   51.05 (+1.90%)
CGC   2.73 (+0.00%)
F   11.20 (+0.00%)
GE   62.42 (+0.82%)
DIS   95.08 (+0.80%)
AMC   6.77 (-2.87%)
PYPL   86.16 (+0.10%)
PFE   44.07 (+0.71%)
NFLX   236.51 (+0.45%)
S&P 500   3,624.92 (+1.10%)
DOW   29,078.49 (+1.23%)
QQQ   269.11 (+0.69%)
AAPL   138.12 (-0.06%)
MSFT   235.25 (+1.01%)
META   136.82 (+0.84%)
GOOGL   96.71 (+1.11%)
AMZN   113.66 (+0.58%)
TSLA   247.40 (-6.73%)
NVDA   122.36 (+0.80%)
NIO   15.48 (-1.84%)
BABA   79.04 (-1.19%)
AMD   64.36 (+1.58%)
T   15.84 (+3.26%)
MU   51.05 (+1.90%)
CGC   2.73 (+0.00%)
F   11.20 (+0.00%)
GE   62.42 (+0.82%)
DIS   95.08 (+0.80%)
AMC   6.77 (-2.87%)
PYPL   86.16 (+0.10%)
PFE   44.07 (+0.71%)
NFLX   236.51 (+0.45%)
NASDAQ:ATHX

Athersys - ATHX Stock Forecast, Price & News

$1.80
-0.05 (-2.70%)
(As of 10/3/2022 09:32 AM ET)
Add
Compare
Today's Range
$1.80
$1.86
50-Day Range
$1.17
$8.13
52-Week Range
$1.13
$35.50
Volume
810 shs
Average Volume
616,034 shs
Market Capitalization
$19.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Athersys MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
236.0% Upside
$6.25 Price Target
Short Interest
Healthy
4.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of Athersys in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($8.34) to ($8.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

1005th out of 1,093 stocks

Pharmaceutical Preparations Industry

501st out of 548 stocks

ATHX stock logo

About Athersys (NASDAQ:ATHX) Stock

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Stock News Headlines

Athersys Announces 1-for-25 Reverse Stock Split
See More Headlines
Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Company Calendar

Last Earnings
8/11/2022
Today
10/03/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
104
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$6.25
Low Stock Price Forecast
$6.25
Forecasted Upside/Downside
+247.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-86,960,000.00
Net Margins
-779.67%
Pretax Margin
-779.67%

Debt

Sales & Book Value

Annual Sales
$5.51 million
Book Value
$1.74 per share

Miscellaneous

Free Float
9,970,000
Market Cap
$19.81 million
Optionable
Optionable
Beta
-0.79

Social Links


Key Executives

  • Mr. Daniel A. Camardo M.B.A. (Age 53)
    CEO, Sec., Principal Accounting Officer & Director
  • Ms. Z. Kasey Rosado
    Interim Chief Financial Officer
  • Ms. Maia A. Hansen M.B.A. (Age 53)
    M.S., Chief Operating Officer
  • Ms. Alison O'Sullivan M.B.A.
    VP of HR
  • Dr. Manal Morsy M.B.A.
    M.D., PH.D., Exec. VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays Ph.D.
    Exec. VP, Head of Regenerative Medicine & Neuroscience Programs
  • Mr. Rakesh Ramachandran MS
    Head of Information Technology & Communications and VP
  • Mr. James Glover B.S.
    P.M.P., Exec. VP & Head of Manufacturing













ATHX Stock - Frequently Asked Questions

Should I buy or sell Athersys stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" ATHX shares.
View ATHX analyst ratings
or view top-rated stocks.

What is Athersys' stock price forecast for 2022?

1 Wall Street research analysts have issued 12 month target prices for Athersys' shares. Their ATHX share price forecasts range from $6.25 to $6.25. On average, they predict the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 237.8% from the stock's current price.
View analysts price targets for ATHX
or view top-rated stocks among Wall Street analysts.

How have ATHX shares performed in 2022?

Athersys' stock was trading at $22.5650 on January 1st, 2022. Since then, ATHX shares have decreased by 91.8% and is now trading at $1.85.
View the best growth stocks for 2022 here
.

When is Athersys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ATHX earnings forecast
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($2.25) EPS for the quarter, missing analysts' consensus estimates of ($1.75) by $0.50. Athersys had a negative trailing twelve-month return on equity of 977.13% and a negative net margin of 779.67%. During the same period last year, the business earned ($2.50) EPS.

When did Athersys' stock split?

Shares of Athersys reverse split on the morning of Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?
What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.85.

How much money does Athersys make?

Athersys (NASDAQ:ATHX) has a market capitalization of $20.35 million and generates $5.51 million in revenue each year. The biopharmaceutical company earns $-86,960,000.00 in net income (profit) each year or ($8.50) on an earnings per share basis.

How many employees does Athersys have?

The company employs 104 workers across the globe.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.

This page (NASDAQ:ATHX) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.